Mitral Regurgitation Clinical Presentation

  • Author: Ivan Hanson, MD; Chief Editor: Richard A Lange, MD   more...
 
Updated: Oct 7, 2011
 

History

Acute mitral regurgitation

When associated with coronary artery disease and acute myocardial infarction (typically, inferior myocardial infarction, which may lead to papillary muscle dysfunction), significant acute mitral regurgitation (MR) is accompanied by symptoms of impaired LV function, such as dyspnea, fatigue, and orthopnea. In these cases, pulmonary edema is often the initial manifestation because of rapid volume overload on the left atrium and the pulmonary venous system.

Chronic mitral regurgitation

  • Often results from a primary defect of the mitral valve apparatus with subsequent progressive enlargement of the left atrium and ventricle. In this state, patients may remain asymptomatic for years.
  • Patients may have normal exercise tolerance until systolic dysfunction of the LV develops, at which point they may experience symptoms of a reduced forward cardiac output (ie, fatigue, dyspnea on exertion, or shortness of breath).
  • With time, patients may feel chest palpitations if atrial fibrillation develops as a result of chronic atrial dilatation. For related information, see Medscape's Atrial Fibrillation Resource Center.
  • Patients with LV enlargement and more severe disease eventually progress to symptomatic congestive heart failure with pulmonary congestion and edema. At this stage of LV dilatation, the myocardial dysfunction often becomes irreversible. For related information, see Medscape's Heart Failure Resource Center.
Next

Physical

Palpation

  • Brisk carotid upstroke and hyperdynamic cardiac impulse
  • Prominent LV filling wave may be present

Auscultation

  • S1 may be diminished in acute MR and chronic severe MR with defective valve leaflets.
  • Wide splitting of S2 may occur due to early closure of the aortic valve.
  • S3 may be present due to LV dysfunction or as a result of increased blood flow across the mitral valve.
  • P2 may be accentuated if pulmonary hypertension is present.
  • Murmur
    • Quality
      • Usually high-pitched, blowing
    • Location
      • Usually best heard over the apex
      • Usually radiates to the left axilla or subscapular region
        • Posterior leaflet dysfunction causes murmur to radiate to the sternum or aortic area
        • Anterior leaflet dysfunction causes murmur to radiate to the back or top of the head
    • Duration
      • Usually holosystolic
      • May be confined to early systole in acute MR
      • May be confined to late systole in MVP or papillary muscle dysfunction
        • S1 will probably be normal in these cases since initial closure of mitral valve cusps is unimpeded.
        • A midsystolic click preceding murmur is suggestive of MVP.
    • Intensity
      • Little correlation exists between intensity of murmur and severity of MR.
      • Intensity may be diminished in severe MR caused by LV dysfunction, acute myocardial infarction, or periprosthetic valve regurgitation.
Previous
Next

Causes

Acute mitral regurgitation

  • Coronary artery disease (ischemia or acute myocardial infarction)
    • Papillary muscle dysfunction
      • The posteromedial papillary muscle is supplied by the terminal branch of the posterior descending artery and is more vulnerable to ischemic insult than the anterolateral papillary muscle, which is usually supplied by both the left anterior descending and circumflex arteries.
      • Transient ischemia may result in transient MR associated with angina.
      • Myocardial infarction or severe prolonged ischemia produces irreversible papillary muscle dysfunction and scarring.
    • Chordae tendineae dysfunction or rupture
  • Infectious endocarditis
    • Abscess formation
    • Vegetations
    • Rupture of chordae tendineae
    • Leaflet perforation
  • Status post valvular surgery
    • Trauma
    • Percutaneous valvuloplasty
    • Suture interruption
  • Tumors (most commonly atrial myxoma)
  • Myxomatous degeneration
    • Mitral valve prolapse
    • Ehlers-Danlos syndrome
    • Marfan syndrome
  • Systemic lupus erythematosus (Libman-Sacks lesion)
  • Acute rheumatic fever (Carey Coombs murmur)
  • Acute global left ventricular dysfunction
  • Prosthetic mitral valve dysfunction

Chronic mitral regurgitation

  • Rheumatic heart disease
  • Systemic lupus erythematosus
  • Scleroderma
  • Myxomatous degeneration
    • Mitral valve prolapse
    • Ehlers-Danlos syndrome
    • Marfan syndrome
  • Calcification of mitral valve annulus
  • Infective endocarditis (can affect normal, abnormal, or prosthetic mitral valves)
  • Ruptured chordae tendineae
    • Trauma
    • Mitral valve prolapse
    • Endocarditis
    • Spontaneous
  • Functional MR
    • Dilation of mitral valve annulus
    • Abnormal tethering of leaflets due to enlargement of LV cavity and stretch of papillary muscles and chordae
      • Dilated cardiomyopathies
      • Aneurysmal dilation of the left ventricle
  • Hypertrophic cardiomyopathy
    • Systolic anterior motion of the mitral valve
  • Perivalvular prosthetic leak
  • Congenital
    • Mitral valve clefts
    • Mitral valve fenestrations
    • Parachute mitral valve abnormality
  • Drug-related
    • Ergotamine, methysergide, pergolide, anorexiant medications
Previous
 
 
Contributor Information and Disclosures
Author

Ivan Hanson, MD  Fellow, Department of Cardiovascular Disease, William Beaumont Hospital

Ivan Hanson, MD, is a member of the following medical societies: American College of Cardiology and American College of Physicians

Disclosure: Nothing to disclose.

Coauthor(s)

Luis C Afonso, MD  Assistant Professor, Department of Internal Medicine-Cardiology, Program Director of Cardiology Fellowship Program, Wayne State University; Director of Echocardiography Laboratory, Harper University Hospital

Luis C Afonso, MD is a member of the following medical societies: American College of Cardiology, American College of Physicians, American Medical Association, and American Society of Echocardiography

Disclosure: Nothing to disclose.

Specialty Editor Board

Martin Keane, MD, FACC, FAHA  Associate Professor, Cardiovascular Medicine Division, Department of Medicine, University of Pennsylvania School of Medicine

Martin Keane, MD, FACC, FAHA is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Heart Association, American Society of Echocardiography, Pennsylvania Medical Society, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Ronald J Oudiz, MD, FACP, FACC, FCCP  Professor of Medicine, University of California, Los Angeles, David Geffen School of Medicine; Director, Liu Center for Pulmonary Hypertension, Division of Cardiology, LA Biomedical Research Institute at Harbor-UCLA Medical Center

Ronald J Oudiz, MD, FACP, FACC, FCCP is a member of the following medical societies: American College of Cardiology, American College of Chest Physicians, American College of Physicians, American Heart Association, and American Thoracic Society

Disclosure: Actelion Grant/research funds Clinical Trials + honoraria; Encysive Grant/research funds Clinical Trials + honoraria; Gilead Grant/research funds Clinical Trials + honoraria; Pfizer Grant/research funds Clinical Trials + honoraria; United Therapeutics Grant/research funds Clinical Trials + honoraria; Lilly Grant/research funds Clinical Trials + honoraria; LungRx Clinical Trials + honoraria; Bayer Grant/research funds Consulting

Amer Suleman, MD  Private Practice

Amer Suleman, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Institute of Stress, American Society of Hypertension, Federation of American Societies for Experimental Biology, Royal Society of Medicine, and Society of Cardiac Angiography and Interventions

Disclosure: Nothing to disclose.

Chief Editor

Richard A Lange, MD  Professor and Executive Vice Chairman, Department of Medicine, Director, Office of Educational Programs, University of Texas Health Science Center at San Antonio

Richard A Lange, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Cardiology, American Heart Association, and Association of Subspecialty Professors

Disclosure: Nothing to disclose.

Additional Contributors

The authors and editors of eMedicine gratefully acknowledge the contributions of previous authors Shivkumar H Jha, MD; Jatin Dave, MD, MPH; Kishorkumar Desai, MD; and Abraham G Kocheril, MD, FACC, FACP to the development and writing of this article.

References
  1. Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation. Aug 1 2006;114(5):e84-231. [Medline].

  2. [Best Evidence] Pizarro R, Bazzino OO, Oberti PF, Falconi M, Achilli F, Arias A, et al. Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation. J Am Coll Cardiol. Sep 15 2009;54(12):1099-106. [Medline].

  3. [Guideline] Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. Oct 9 2007;116(15):1736-54. [Medline].

  4. Barbieri A, Bursi F, Grigioni F, Tribouilloy C, Avierinos JF, Michelena HI, et al. Prognostic and therapeutic implications of pulmonary hypertension complicating degenerative mitral regurgitation due to flail leaflet: A Multicenter Long-term International Study. Eur Heart J. Mar 2011;32(6):751-759. [Medline].

  5. Feldman T, Cilingiroglu M. Percutaneous leaflet repair and annuloplasty for mitral regurgitation. J Am Coll Cardiol. Feb 1 2011;57(5):529-37. [Medline].

  6. Feldman T, Foster E, Glower DG, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. Apr 14 2011;364(15):1395-406. [Medline].

  7. Rossi A, Dini FL, Faggiano P, et al. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. Heart. Oct 2011;97(20):1675-80. [Medline].

  8. [Best Evidence] Tribouilloy C, Grigioni F, Avierinos JF, Barbieri A, Rusinaru D, Szymanski C, et al. Survival implication of left ventricular end-systolic diameter in mitral regurgitation due to flail leaflets a long-term follow-up multicenter study. J Am Coll Cardiol. Nov 17 2009;54(21):1961-8. [Medline].

  9. Magne J, Lancellotti P, O'Connor K, et al. Prediction of exercise pulmonary hypertension in asymptomatic degenerative mitral regurgitation. J Am Soc Echocardiogr. Sep 2011;24(9):1004-12. [Medline].

  10. Bonow RO, Cheitlin MD, Crawford MH, Douglas PS. Task Force 3: valvular heart disease. J Am Coll Cardiol. Apr 19 2005;45(8):1334-40. [Medline].

  11. Carabello BA. Progress in mitral and aortic regurgitation. Prog Cardiovasc Dis. May-Jun 2001;43(6):457-75. [Medline].

  12. Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, Detaint D, Capps M, Nkomo V, et al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med. Mar 3 2005;352(9):875-83. [Medline].

  13. Fann JI, Ingels NB, Miller DC. Pathophysiology of Mitral Valve Disease. In: Cardiac Surgery in the Adult. 3rd ed. New York, NY: McGraw-Hill; 2008:chap 41.

  14. Khanna D, Miller AP, Nanda NC, et al. Transthoracic and transesophageal echocardiographic assessment of mitral regurgitation severity: usefulness of qualitative and semiquantitative techniques. Echocardiography. Oct 2005;22(9):748-69. [Medline].

  15. Libby P, Bonow RO, MD, Zipes DP, Mann DL. Valvular Heart Disease. In: Braunwald's Heart Disease. 8th ed. Philadelphia, PA: Saunders Elsevier; 2008:chap. 62.

  16. Matsunaga A, Duran CM. Progression of tricuspid regurgitation after repaired functional ischemic mitral regurgitation. Circulation. Aug 30 2005;112(9 Suppl):I453-7. [Medline].

  17. Mehta RH, Eagle KA, Coombs LP, Peterson ED, Edwards FH, Pagani FD, et al. Influence of age on outcomes in patients undergoing mitral valve replacement. Ann Thorac Surg. Nov 2002;74(5):1459-67. [Medline].

  18. Rosenhek R, Rader F, Klaar U, Gabriel H, Krejc M, Kalbeck D, et al. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation. May 9 2006;113(18):2238-44. [Medline].

  19. Thourani VH, Weintraub WS, Guyton RA, Jones EL, Williams WH, Elkabbani S, et al. Outcomes and long-term survival for patients undergoing mitral valve repair versus replacement: effect of age and concomitant coronary artery bypass grafting. Circulation. Jul 22 2003;108(3):298-304. [Medline].

Previous
Next
 
Transthoracic echocardiogram demonstrating severe mitral regurgitation with heavily calcified mitral valve and prolapse of the posterior leaflet into the left atrium.
Transesophageal echocardiogram demonstrating prolapse of both mitral valve leaflets during systole.
Transthoracic echocardiogram demonstrating bioprosthetic mitral valve dehiscence with paravalvular regurgitation.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.